In a new study by researchers at Yale Cancer Center, combining the immunotherapy drug durvalumab and PARP-inhibitor olaparib with chemotherapy improved response to treatment for women with high-risk, HER2-negative breast cancer, including a subset of estrogen receptor positive cancers.
Queen Sirikit Center for Breast Cancer, King Chulalongkorn Memorial Hospital, Thai Red Cross Society (Chulalongkorn Hospital) has become the world’s first institution to have successfully used immunotherapy to treat a breast cancer patient who is now in complete remission with minimal side effects and uplifted quality of life.
Through large-scale profiling of protein changes in response to drug treatments in cancer cell lines, researchers at The University of Texas MD Anderson Cancer Center have generated a valuable resource to aid in predicting drug sensitivity, to understand therapeutic resistance mechanisms and to identify optimal combination treatment strategies.
Researchers reporting in ACS’ Nano Letters have developed nanoparticles that release bursts of calcium inside tumor cells, inhibiting drug pumps and reversing MDR.
Groundbreaking cancer research by the University of South Australia has identified an invasive protein molecule that could be responsible for some of the most aggressive breast cancers.
Weizmann Institute scientists show that bacteria live inside all cancer cells, from brain to breast to bone, and that each type of cancer has its own type of bacteria. Understanding this relationship could help predict treatment effectiveness or lead to ways of using the bacteria to boost treatments.